Disclosed are novel nitrilated psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The compounds may be produced by reacting a reactant psilocybin derivative with a nitrile-group containing compound.

Disclosed are novel nitrilated psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The compounds may be produced by reacting a reactant psilocybin derivative with a nitrile-group containing compound.

Compositions and methods are provided comprising acetolactate decarboxylase (ALDC) enzyme variants having higher specific activity. Composition and method are provided where the ALDC variants are used in combination with metal ions to further increase stability and/or activity.

Compositions and methods are provided comprising acetolactate decarboxylase (ALDC) enzyme variants having higher specific activity. Composition and method are provided where the ALDC variants are used in combination with metal ions to further increase stability and/or activity.

The present disclosure provides recombinant microorganisms and methods for the anaerobic production of 2,4-furandimethanol from one or more carbon sources. The microorganisms and methods provide redox-balanced and ATP positive pathways for co-producing 2,4-furandimethanol with ethanol and for co-producing 2,4-furandimethanol with ethanol and acetone and/or isopropanol. The method provides recombinant microorganisms that express endogenous and/or exogenous nucleic acid molecules encoding polypeptides that catalyze the conversion of a carbon source into 2,4-furandimethanol and that couple the 2,4-furandimethanol pathway with an additional metabolic pathway. The present disclosure further provides enzymatic production of 2,4-furandicarboxylic acid.

The present disclosure provides recombinant microorganisms and methods for the anaerobic production of 2,4-furandimethanol from one or more carbon sources. The microorganisms and methods provide redox-balanced and ATP positive pathways for co-producing 2,4-furandimethanol with ethanol and for co-producing 2,4-furandimethanol with ethanol and acetone and/or isopropanol. The method provides recombinant microorganisms that express endogenous and/or exogenous nucleic acid molecules encoding polypeptides that catalyze the conversion of a carbon source into 2,4-furandimethanol and that couple the 2,4-furandimethanol pathway with an additional metabolic pathway. The present disclosure further provides enzymatic production of 2,4-furandicarboxylic acid.

Increasing space-time-yield, carbon-conversion-efficiency and carbon substrate flexibility in the production of fine chemicals The inventors of the current invention have found a surprising positive effect of increased cAMP levels and/or manipulating the PTS system on the space-time-yield, carbon-conversion-efficiency and carbon substrate flexibility of fine chemical production of a host organism. This was achieved by de-regulating adenylate cyclase cyaa by deleting the C-terminal regulatory region leading to increased cAMP levels or deleting the Crr protein activity (carbohydrate repression resistance) which regulates the carbohydrate utilization system. Both lead to increased 2-fucosyllactoe and 6-sialyllactose production (human milk oligosaccharides) and increase carbohydrate usage.

Increasing space-time-yield, carbon-conversion-efficiency and carbon substrate flexibility in the production of fine chemicals The inventors of the current invention have found a surprising positive effect of increased cAMP levels and/or manipulating the PTS system on the space-time-yield, carbon-conversion-efficiency and carbon substrate flexibility of fine chemical production of a host organism. This was achieved by de-regulating adenylate cyclase cyaa by deleting the C-terminal regulatory region leading to increased cAMP levels or deleting the Crr protein activity (carbohydrate repression resistance) which regulates the carbohydrate utilization system. Both lead to increased 2-fucosyllactoe and 6-sialyllactose production (human milk oligosaccharides) and increase carbohydrate usage.

This invention is an improved method of robust and scalable production of precursors of active cannabinoids, including geranyl pyrophosphate (GPP) and/or cannabigerolic acid (CBGA), in a methylotrophic yeast host cell. The improved methods incorporate a polypeptide encoding an Erg20 variant (F98W/N128W) into a methylotrophic yeast host cell, for example Pichia pastoris (Komagataella phaffii), that biases the natural production of FPP and GPP towards GPP, a precursor to the intermediate CBGA, crucial to the synthesis of active cannabinoids.

Disclosed are novel hydroxylated psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The compounds may be produced synthetically or biosynthetically.